Overview

Nelfinavir and M8 Drug-level Monitoring in HIV-1 Infection

Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the impact of prospective drug level monitoring and dose-adjustment of nelfinavir (NFV) on the clinical and virologic outcomes in a group of HIV-infected patients who have achieved virologic success while receiving a nelfinavir containing highly active antiretroviral therapy (HAART) regimen.
Phase:
N/A
Details
Lead Sponsor:
University of Wisconsin, Madison
Collaborator:
Agouron Pharmaceuticals
Treatments:
Nelfinavir